Susan Bryce
28/05/1983
Email hidden; Javascript is required.
Assessments
 Date Created Name Email Case Status Approved Date
8 September 2026Susan BryceEmail hidden; Javascript is required.Consultation Complete10/09/2026
 Date Created Name Email Case Status Approved Date
Follow-up
 Date Created Name Date of Birth Current Weight Current Weight (KG) Current Height (CM) BMI Height Feet Inches Weight Stones Pounds Your BMI Follow-Up Status
15 October 2026Susie Bryce28/05/198353101226.924206027802New
 Date Created Name Date of Birth Current Weight Current Weight (KG) Current Height (CM) BMI Height Feet Inches Weight Stones Pounds Your BMI Follow-Up Status
Add Prescription
Prescriptions
 Date of Prescription Prescription ID Name Prescriber NameItems StatusPrint
16/10/2026Rx00117Susan BryceAnna FenechWegovy 0.5mg pre-filled pen - inject once weekly as directed

Dispensed ➡️ Print Dispense Label
➡️ Print Prescritpion
➡️ Print Bag Label
15/09/2026Rx00091Susan BryceAnna FenechWegovy 0.25mg pre-filled pen - inject once weekly as directed

Dispensed ➡️ Print Dispense Label
➡️ Print Prescritpion
➡️ Print Bag Label
 Date of Prescription Prescription ID Name Prescriber NameItems StatusPrint
Add Consultation
Consultations
Date
Consultation Title
follow up
Consultation Type
Follow-up
BMI
0

client completed follow up questionnaires, no changes in medical history, feels like weight loss slow down and require dose increase, prescription for Wegovy 0.5mg issued

Date
Consultation Title
follow up
BMI
0

left message

Date
Consultation Title
follow up call
BMI
0

first injection administered correctly, suffered nausea for two days a day after the injection, no other side effects, advice given how to manage, appetite reduced,

Date
Consultation Title
initial consultation
Consultation Type
Initial
Weight (kg)
72
Height (cm)
160
BMI
28.125

Medical history and current medication reviewed. Client reports occasional migraine, managed with naproxen and rizatriptan as required. Currently taking the oral contraceptive pill. BMI 28 kg/m² and waist circumference 90 cm. Assessment consistent with overweight with central adiposity. Client's weight-loss goal is 9 kg.

Discussed treatment with Wegovy (semaglutide) and mechanism of action, including appetite regulation and increased satiety. Benefits, risks and potential adverse effects discussed, including nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite. Advised regarding dietary measures, smaller portion sizes and adequate fluid intake.

Contraception reviewed and advice provided regarding continued effective contraception. Advised that vomiting or severe diarrhoea may affect absorption of the oral contraceptive pill and to follow contraceptive guidance regarding additional precautions if required.

Following discussion, client wishes to proceed with treatment. Wegovy 0.25 mg subcutaneously once weekly commenced as prescribed. Advised to continue dietary and lifestyle measures. Weight, waist circumference, treatment response and tolerability to be monitored, with review prior to dose escalation. Weight-loss target is 9 kg.

Dispensed
 Dispensed Date NameRx SummaryActionsPrint Pack
21/10/2026Susan Bryce Item 1: Wegovy 0.5mg pre-filled pen
Qty: 1
Directions: inject once weekly as directed

Prescription
Dispense Label

Bag Label
16/09/2026Susan Bryce Item 1: Wegovy 0.25mg pre-filled pen
Qty: 1
Directions: inject once weekly as directed

Prescription
Dispense Label

Bag Label
 Dispensed Date NameRx SummaryActionsPrint Pack
Purchase History
Order Date Status Total
#2218 16/10/2026 Completed £131.24
#2151 15/09/2026 Completed £96.24

This email is already registered

Please log in to continue your assessment. Once logged in, you will be returned to this page.